MICHAEL FRUMOVITZ to Bevacizumab
This is a "connection" page, showing publications MICHAEL FRUMOVITZ has written about Bevacizumab.
Connection Strength
0.348
-
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study. Am J Obstet Gynecol. 2023 04; 228(4):445.e1-445.e8.
Score: 0.159
-
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix. Gynecol Oncol. 2017 Jan; 144(1):46-50.
Score: 0.104
-
Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol. 2007 Mar; 104(3):768-78.
Score: 0.053
-
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol Oncol. 2019 06; 153(3):541-548.
Score: 0.031